Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

2.9%

2 terminated/withdrawn out of 70 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

23%

16 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

15 recruiting

Enrollment Performance

Analytics

N/A
20(40.8%)
Phase 2
10(20.4%)
Phase 3
9(18.4%)
Phase 4
7(14.3%)
Phase 1
2(4.1%)
Early Phase 1
1(2.0%)
49Total
N/A(20)
Phase 2(10)
Phase 3(9)
Phase 4(7)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials
NCT06928376Phase 2Recruiting

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Role: collaborator

NCT06609759Active Not Recruiting

Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer

Role: collaborator

NCT07167342Phase 4Not Yet Recruiting

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Role: collaborator

NCT07533825Not ApplicableEnrolling By Invitation

Laparoscopic Staging for Stage III Gastric Cancer

Role: collaborator

NCT06084819Phase 2Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT05871099Phase 3Recruiting

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Role: collaborator

NCT07444099Not ApplicableEnrolling By Invitation

Early Postoperative Intervention in Gastric Cancer Patients

Role: collaborator

NCT07379281Recruiting

Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT06068621Phase 2Completed

Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT07334535Phase 4Not Yet Recruiting

Isa-VRD in TIE HRMM

Role: collaborator

NCT06818305Phase 2Terminated

Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

Role: collaborator

NCT07101770Recruiting

A Prediction Model in Pregnant Women With Aplastic Anemia

Role: collaborator

NCT07239674Phase 3Not Yet Recruiting

Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC

Role: collaborator

NCT07054242Phase 2Not Yet Recruiting

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Role: lead

NCT07152886Phase 4Not Yet Recruiting

The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer

Role: collaborator

NCT07111429Not Yet Recruiting

Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification

Role: collaborator

NCT03850457Completed

Epidemiological Study for Bronchopulmonary Dysplasia (BPD) in China

Role: collaborator

NCT06157216Not ApplicableActive Not Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Role: collaborator